292 related articles for article (PubMed ID: 33558277)
1. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T; Cai J; Botwood NA; Labriola DF
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558277
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
Motzer RJ; Escudier B; McDermott DF; Arén Frontera O; Melichar B; Powles T; Donskov F; Plimack ER; Barthélémy P; Hammers HJ; George S; Grünwald V; Porta C; Neiman V; Ravaud A; Choueiri TK; Rini BI; Salman P; Kollmannsberger CK; Tykodi SS; Grimm MO; Gurney H; Leibowitz-Amit R; Geertsen PF; Amin A; Tomita Y; McHenry MB; Saggi SS; Tannir NM
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661118
[TBL] [Abstract][Full Text] [Related]
3. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
4. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials.
Hu C; Wang M; Wu C; Zhou H; Chen C; Diede S
JAMA Netw Open; 2021 May; 4(5):e218175. PubMed ID: 34047794
[TBL] [Abstract][Full Text] [Related]
6. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis.
Xu Y; Hezam K; Ali MG; Wang Y; Zhang J
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):386-394. PubMed ID: 34014122
[No Abstract] [Full Text] [Related]
8. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Rosner S; Kwong E; Shoushtari AN; Friedman CF; Betof AS; Brady MS; Coit DG; Callahan MK; Wolchok JD; Chapman PB; Panageas KS; Postow MA
Cancer Med; 2018 Mar; 7(3):690-697. PubMed ID: 29468834
[TBL] [Abstract][Full Text] [Related]
12. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Svrcek M; Moss RA; Ledeine JM; Cao ZA; Kamble S; Kopetz S; André T
J Clin Oncol; 2018 Mar; 36(8):773-779. PubMed ID: 29355075
[TBL] [Abstract][Full Text] [Related]
13. Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial.
Othus M; Patel SP; Chae YK; Dietrich E; Streicher H; Sharon E; Kurzrock R
J Natl Cancer Inst; 2024 May; 116(5):673-680. PubMed ID: 38243705
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.
Pelster MS; Gruschkus SK; Bassett R; Gombos DS; Shephard M; Posada L; Glover MS; Simien R; Diab A; Hwu P; Carter BW; Patel SP
J Clin Oncol; 2021 Feb; 39(6):599-607. PubMed ID: 33125309
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM; Panageas KS; Hollmann T; Shoushtari AN; Momtaz P; Chapman PB; Postow MA; Callahan MK; Wolchok JD; Brady MS; Coit DG; Ariyan CE
Ann Surg Oncol; 2020 Apr; 27(4):1180-1188. PubMed ID: 31848819
[TBL] [Abstract][Full Text] [Related]
18. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
Abdelhafeez AAM; Shohdy KS; Ibrahim W
Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
[TBL] [Abstract][Full Text] [Related]
19. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis.
Marchetti P; Botticelli A; Ascierto AP; Curigliano G; Giannarelli D
J Transl Med; 2020 Nov; 18(1):446. PubMed ID: 33239030
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
[Next] [New Search]